The company is initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix is also developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. The test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department, enabling healthcare providers to better diagnose diseases and make more timely and appropriate therapy and level of care decisions.